# An Exploratory Safety and Efficacy Clinical Study of CARDIX-101 for the Treatment of Chronic Bradycardia

> **NCT05117346** · PHASE1,PHASE2 · COMPLETED · sponsor: **Cardix Therapeutics LLC** · enrollment: 20 (actual)

## Conditions studied

- Bradycardia

## Interventions

- **DRUG:** CARDIX-101A, CARDIX-101B, CARDIX-101C

## Key facts

- **NCT ID:** NCT05117346
- **Lead sponsor:** Cardix Therapeutics LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-01
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2024-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05117346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05117346, "An Exploratory Safety and Efficacy Clinical Study of CARDIX-101 for the Treatment of Chronic Bradycardia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05117346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*